IONIS PHARMACEUTICALS INC — Director's Dealing 2020

Jan 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2020-01-15

Reporting Person: HOUGEN ELIZABETH L (SVP, Finance & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-15	Common Stock	M	12044	—	Acquired	36504	Direct
2020-01-15	Common Stock	F	4277	$62.06	Disposed	32227	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-15	Restricted Stock Units	$	A	26800	Acquired		Common Stock (26800)	Direct
2020-01-15	Restricted Stock Units	$	M	12044	Disposed		Common Stock (12044)	Direct

Footnotes

F1: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F2: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F3: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.